Induction of retinoid resistance in breast cancer cells by overexpression of cJun - PubMed (original) (raw)

. 1997 Oct 15;57(20):4652-61.

Affiliations

• PMID: 9377582

Induction of retinoid resistance in breast cancer cells by overexpression of cJun

L Yang et al. Cancer Res. 1997.

Abstract

To investigate the role of AP-1 transcription factors in mediating retinoid-induced growth suppression of breast cells, we studied the sensitivity of MCF7 breast cancer cells with different levels of AP-1 activity to all-trans retinoic acid (atRA). AP-1 activity was increased in MCF7 cells by stably transfecting c-jun cDNA into these cells. Parental and vector-transfected MCF7 cells, which were sensitive to the growth-inhibitory effects of atRA, exhibited atRA-dependent retinoic acid receptor (RAR) transactivation and transrepression of 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity. The c-jun-transfected MCF7 cells had increased basal AP-1 transactivation activity and increased expression of AP-1-regulated genes but were resistant to the antiproliferative effects of atRA. However, MCF7 cells transfected with a deletion mutant of c-jun, TAM-67, which lacks most of the amino-terminal transactivation domain of cJun and is unable to activate AP-1-dependent gene expression, were sensitive to the growth-inhibitory effects of atRA. These results suggest that the transactivation domain of cJun is required for induction of retinoid resistance in these breast cancer cells. atRA did not activate RAR-dependent gene transcription or transrepress 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity in these cJun-overexpressing cells. Investigation of the RAR and retinoic acid X receptor expression level demonstrated that RAR alpha and RAR gamma RNA expression was reduced in the c-jun-transfected MCF7 cells, whereas RAR beta expression was up-regulated. However, retinoic acid responsive element DNA binding activity was intact in c-jun-transfected cells. Therefore, the mechanism by which cJun overexpression induces resistance to the growth-inhibitory effect of atRA may be through interference with atRA-dependent RAR transactivation or AP-1 transrepression, possibly through titration of essential coactivators. These results suggest that the antiproliferative effects of retinoids can be overcome by cJun overexpression.

PubMed Disclaimer

Similar articles

• Unique anti-activator protein-1 activity of retinoic acid receptor beta.
  Lin F, Xiao D, Kolluri SK, Zhang X. Lin F, et al. Cancer Res. 2000 Jun 15;60(12):3271-80. Cancer Res. 2000. PMID: 10866321
• Retinyl methyl ether down-regulates activator protein 1 transcriptional activation in breast cancer cells.
  Agadir A, Shealy YF, Hill DL, Zhang X. Agadir A, et al. Cancer Res. 1997 Aug 15;57(16):3444-50. Cancer Res. 1997. PMID: 9270011
• Complexity, retinoid-responsive gene networks, and bladder carcinogenesis.
  Hurst RE, Waliszewski P, Waliszewska M, Bonner RB, Benbrook DM, Dar A, Hemstreet GP 3rd. Hurst RE, et al. Adv Exp Med Biol. 1999;462:449-67. doi: 10.1007/978-1-4615-4737-2_35. Adv Exp Med Biol. 1999. PMID: 10599447 Review.
• The ying-yang of RAR and AP-1: cancer treatment without overt toxicity.
  Allenby G. Allenby G. Hum Exp Toxicol. 1995 Feb;14(2):226-30. doi: 10.1177/096032719501400214. Hum Exp Toxicol. 1995. PMID: 7779452 Review. No abstract available.

Cited by

• Ethanol Extract of Sargassum siliquastrum Inhibits Lipopolysaccharide-Induced Nitric Oxide Generation by Downregulating the Nuclear Factor-Kappa B Signaling Pathway.
  Min HY, Kim H, Lee HJ, Yoon NY, Kim YK, Lee HY. Min HY, et al. Evid Based Complement Alternat Med. 2022 Jun 10;2022:6160010. doi: 10.1155/2022/6160010. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35722164 Free PMC article.
• Protein Kinase C Alpha (PKCα) overexpression leads to a better response to retinoid acid therapy through Retinoic Acid Receptor Beta (RARβ) activation in mammary cancer cells.
  Bessone MID, Berardi DE, Cirigliano SM, Delbart DI, Peters MG, Todaro LB, Urtreger AJ. Bessone MID, et al. J Cancer Res Clin Oncol. 2020 Dec;146(12):3241-3253. doi: 10.1007/s00432-020-03368-7. Epub 2020 Aug 31. J Cancer Res Clin Oncol. 2020. PMID: 32865619
• Retinoic Acids in the Treatment of Most Lethal Solid Cancers.
  Costantini L, Molinari R, Farinon B, Merendino N. Costantini L, et al. J Clin Med. 2020 Jan 28;9(2):360. doi: 10.3390/jcm9020360. J Clin Med. 2020. PMID: 32012980 Free PMC article. Review.
• Novel Clofarabine-Based Combinations with Polyphenols Epigenetically Reactivate Retinoic Acid Receptor Beta, Inhibit Cell Growth, and Induce Apoptosis of Breast Cancer Cells.
  Lubecka K, Kaufman-Szymczyk A, Cebula-Obrzut B, Smolewski P, Szemraj J, Fabianowska-Majewska K. Lubecka K, et al. Int J Mol Sci. 2018 Dec 10;19(12):3970. doi: 10.3390/ijms19123970. Int J Mol Sci. 2018. PMID: 30544666 Free PMC article.
• Tristetraprolin induces cell cycle arrest in breast tumor cells through targeting AP-1/c-Jun and NF-κB pathway.
  Xu L, Ning H, Gu L, Wang Q, Lu W, Peng H, Cui W, Ying B, Ross CR, Wilson GM, Wei L, Wold WS, Liu J. Xu L, et al. Oncotarget. 2015 Dec 8;6(39):41679-91. doi: 10.18632/oncotarget.6149. Oncotarget. 2015. PMID: 26497679 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Miscellaneous

  • NCI CPTAC Assay Portal